

Michael Murray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4422960/publications.pdf>

Version: 2024-02-01

106
papers

3,133
citations

126708

33
h-index

182168

51
g-index

107
all docs

107
docs citations

107
times ranked

3230
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. <i>Hepatology</i> , 1995, 21, 120-128.	3.6	192
2	P450 Enzymes. <i>Clinical Pharmacokinetics</i> , 1992, 23, 132-146.	1.6	157
3	Mechanisms of Inhibitory and Regulatory Effects of Methylenedioxyphenyl Compounds on Cytochrome P450-Dependent Drug Oxidation. <i>Current Drug Metabolism</i> , 2000, 1, 67-84.	0.7	144
4	Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis. <i>Current Drug Metabolism</i> , 2006, 7, 67-81.	0.7	134
5	Modulation of angiogenesis by ω -3 polyunsaturated fatty acids is mediated by cyclooxygenases. <i>Blood</i> , 2008, 111, 3514-3521.	0.6	113
6	Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 871-885.	1.2	95
7	Pharmacogenetics of Phase I and Phase II Drug Metabolism. <i>Current Pharmaceutical Design</i> , 2010, 16, 204-219.	0.9	94
8	Mechanisms of the Inhibition of Cytochrome P 450-Mediated Drug Oxidation by Therapeutic Agents. <i>Drug Metabolism Reviews</i> , 1987, 18, 55-81.	1.5	83
9	Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. <i>British Journal of Pharmacology</i> , 2010, 161, 1059-1069.	2.7	73
10	Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. , 2015, 150, 109-128.		61
11	Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 21-36.	6.6	61
12	DRUG-MEDIATED INACTIVATION OF CYTOCHROME P450. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997, 24, 465-470.	0.9	59
13	Effects of dihydrosafrole on cytochromes P-450 and drug oxidation in hepatic microsomes from control and induced rats. <i>Toxicology and Applied Pharmacology</i> , 1983, 68, 66-76.	1.3	56
14	Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor α . <i>Gastroenterology</i> , 1995, 109, 198-205.	0.6	55
15	Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1851-1857.	1.7	55
16	The ω -3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation. <i>British Journal of Pharmacology</i> , 2011, 162, 1143-1155.	2.7	50
17	Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. <i>Biochemical Pharmacology</i> , 2012, 84, 215-223.	2.0	50
18	CYP-Mediated Clozapine Interactions: How Predictable Are They?. <i>Current Drug Metabolism</i> , 2007, 8, 307-313.	0.7	49

#	ARTICLE	IF	CITATIONS
19	In vitro effects of quinoline derivatives on cytochrome p-450 and aminopyrine n-demethylase activity in rat hepatic microsomes. <i>Biochemical Pharmacology</i> , 1984, 33, 3277-3281.	2.0	46
20	Impaired androgen 16 β -hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats. <i>Gastroenterology</i> , 1987, 93, 141-147.	0.6	46
21	Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. <i>Biochemical Journal</i> , 2003, 373, 669-680.	1.7	46
22	Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. <i>Current Drug Metabolism</i> , 2009, 10, 643-658.	0.7	44
23	Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease. <i>British Journal of Pharmacology</i> , 2017, 174, 1908-1924.	2.7	44
24	A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 875, 522-530.	1.2	42
25	Complexation of cytochrome P-450 isozymes in hepatic microsomes from SKF 525-A-induced rats. <i>Archives of Biochemistry and Biophysics</i> , 1988, 262, 381-388.	1.4	41
26	Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. <i>British Journal of Pharmacology</i> , 2011, 162, 1380-1388.	2.7	41
27	Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. <i>AAPS Journal</i> , 2013, 15, 1099-1108.	2.2	41
28	In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver. <i>Biochemical Pharmacology</i> , 1991, 42, 2107-2114.	2.0	38
29	Increased expression of cytochrome P450 IIIA2 in male rat liver after dietary vitamin A supplementation. <i>Archives of Biochemistry and Biophysics</i> , 1991, 286, 618-624.	1.4	37
30	Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis. <i>Hepatology</i> , 1995, 22, 580-587.	3.6	37
31	Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 770-777.	1.3	37
32	Human cytochrome P450 isoforms. <i>Gastroenterology</i> , 1990, 99, 885-889.	0.6	35
33	A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 239-246.	1.0	34
34	Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). <i>British Journal of Pharmacology</i> , 2010, 159, 419-427.	2.7	34
35	Synthetic ω -3 Epoxyfatty Acids As Antiproliferative and Pro-apoptotic Agents in Human Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7459-7464.	2.9	33
36	Inhibition and metabolite complexation of rat hepatic microsomal cytochrome p450 by tricyclic antidepressants. <i>Biochemical Pharmacology</i> , 1992, 43, 2065-2071.	2.0	30

#	ARTICLE	IF	CITATIONS
37	Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2547-2555.	1.7	30
38	Participation of a cytochrome P450 enzyme from the 2C subfamily in progesterone 21-hydroxylation in sheep liver. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 43, 591-593.	1.2	29
39	CYP2J2 "regulation, function and polymorphism. <i>Drug Metabolism Reviews</i> , 2016, 48, 351-368.	1.5	29
40	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species. <i>Biochemical Pharmacology</i> , 2017, 143, 79-89.	2.0	29
41	A novel synthetic analogue of ω -17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. <i>FASEB Journal</i> , 2017, 31, 5246-5257.	0.2	29
42	Selective reactivation of steroid hydroxylases following dissociation of the isosafrole metabolite complex with rat hepatic cytochrome P-450. <i>Archives of Biochemistry and Biophysics</i> , 1986, 251, 471-478.	1.4	28
43	Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7163-7172.	2.9	28
44	Up-Regulation of Human CYP2J2 in HepG2 Cells by Butylated Hydroxyanisole Is Mediated by c-Jun and Nrf2. <i>Molecular Pharmacology</i> , 2010, 77, 987-994.	1.0	26
45	PDZK1 and NHERF1 Regulate the Function of Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) by Modulating Its Subcellular Trafficking and Stability. <i>PLoS ONE</i> , 2014, 9, e94712.	1.1	24
46	Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kinetics and application. <i>Tetrahedron</i> , 2012, 68, 6065-6070.	1.0	23
47	Characterization of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. <i>Biochemical Journal</i> , 2005, 391, 631-640.	1.7	21
48	The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions. <i>Chinese Medicine</i> , 2020, 15, 71.	1.6	21
49	Putative Transmembrane Domain 6 of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Influences Transporter Substrate Binding, Protein Trafficking, and Quality Control. <i>Molecular Pharmaceutics</i> , 2015, 12, 111-119.	2.3	20
50	Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity. <i>Chemical Research in Toxicology</i> , 2015, 28, 92-102.	1.7	20
51	Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω -3 Fatty Acid Derivatives. <i>Nanomaterials</i> , 2018, 8, 825.	1.9	20
52	Procyanidin B2 and rutin in Ginkgo biloba extracts protect human retinal pigment epithelial (RPE) cells from oxidative stress by modulating Nrf2 and Erk1/2 signalling. <i>Experimental Eye Research</i> , 2021, 207, 108586.	1.2	20
53	Effect of genetic obesity and experimental diabetes on hepatic microsomal mixed function oxidase activities. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 256-263.	1.4	19
54	Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrate stress. <i>British Journal of Pharmacology</i> , 2010, 159, 1440-1449.	2.7	19

#	ARTICLE	IF	CITATIONS
55	Development of new therapeutic options for the treatment of uveal melanoma. <i>FEBS Journal</i> , 2021, 288, 6226-6249.	2.2	19
56	Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. <i>Biochemical Pharmacology</i> , 2005, 69, 709-717.	2.0	17
57	Toxicological Actions of Plant-Derived and Anthropogenic Methylenedioxyphenyl-Substituted Chemicals in Mammals and Insects. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2012, 15, 365-395.	2.9	17
58	A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8661-8666.	2.9	17
59	Methylenedioxyphenyl compounds as inducers of cytochrome P-450 and monooxygenase activity in the southern armyworm (<i>Spodoptera eridania</i>) and the rat. <i>Pesticide Biochemistry and Physiology</i> , 1986, 26, 310-322.	1.6	16
60	Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. <i>Hepatology</i> , 1993, 18, 1224-1231.	3.6	14
61	ω-3 Polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. <i>Phytochemistry Reviews</i> , 2014, 13, 139-156.	3.1	14
62	Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors. <i>Microvascular Research</i> , 2015, 101, 127-134.	1.1	14
63	Aryl urea substituted fatty acids: a new class of protonophoric mitochondrial uncoupler that utilises a synthetic anion transporter. <i>Chemical Science</i> , 2020, 11, 12677-12685.	3.7	14
64	Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 185-196.	1.5	13
65	Restoration of cytochrome P450 2C11 in vitamin A deficient rat liver by exogenous androgen. <i>FASEB Journal</i> , 1996, 10, 1058-1063.	0.2	12
66	Lipid analogues as potential drugs for the regulation of mitochondrial cell death. <i>British Journal of Pharmacology</i> , 2014, 171, 2051-2066.	2.7	12
67	Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 400-408.	1.1	11
68	Kava dermopathy in Fiji: an acquired ichthyosis?. <i>International Journal of Dermatology</i> , 2014, 53, 1490-1494.	0.5	11
69	Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2 and CYP3A4 selective Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 388-395.	1.2	11
70	Betulinic acid derivatives can protect human MÄ¼ller cells from glutamate-induced oxidative stress. <i>Experimental Cell Research</i> , 2019, 383, 111509.	1.2	11
71	The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. <i>Biochemical Pharmacology</i> , 2014, 88, 245-252.	2.0	10
72	Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 80, 173-178.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Casein Kinase 2 Is a Novel Regulator of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Trafficking. <i>Molecular Pharmaceutics</i> , 2016, 13, 144-154.	2.3	10
74	Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 55-63.	1.9	10
75	Simvastatin protects photoreceptors from oxidative stress induced by all-trans retinal, through the up-regulation of interphotoreceptor retinoid binding protein. <i>British Journal of Pharmacology</i> , 2019, 176, 2063-2078.	2.7	10
76	Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4. <i>AAPS Journal</i> , 2019, 21, 15.	2.2	10
77	Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. <i>FEBS Letters</i> , 2005, 579, 3669-3673.	1.3	9
78	Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2. <i>Biochemical Pharmacology</i> , 2015, 96, 306-314.	2.0	9
79	Compritol solid lipid nanoparticle formulations enhance the protective effect of betulinic acid derivatives in human Müller cells against oxidative injury. <i>Experimental Eye Research</i> , 2022, 215, 108906.	1.2	9
80	The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. <i>Planta Medica</i> , 2021, 87, 511-527.	0.7	8
81	Methylenedioxyphenyl complexes with microsomal cytochrome P-450: In vivo complex formation in rat liver and in midgut tissues of the Southern armyworm (<i>Spodoptera eridania</i>). <i>Pesticide Biochemistry and Physiology</i> , 1987, 28, 140-147.	1.6	7
82	Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes. <i>Current Drug Metabolism</i> , 2010, 11, 850-858.	0.7	7
83	The 5 ϵ -AMP-Activated Protein Kinase Regulates the Function and Expression of Human Organic Anion Transporting Polypeptide 1A2. <i>Molecular Pharmacology</i> , 2018, 94, 1412-1420.	1.0	7
84	The Participation of Cytochrome P450 3A4 in Clozapine Biotransformation Is Detected in People With Schizophrenia by High-Throughput In Vivo Phenotyping. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 629-631.	0.7	6
85	Facile and Stereoselective Synthesis of (Z)-15-Octadecenoic Acid and (Z)-16-Nonadecenoic Acid: Monounsaturated Omega-3 Fatty Acids. <i>Lipids</i> , 2010, 45, 159-165.	0.7	6
86	Cytochromes P450: decision-making tools for personalized therapeutics. <i>Current Opinion in Molecular Therapeutics</i> , 2006, 8, 480-6.	2.8	6
87	All-trans-retinoic acid 4-hydroxylation in human liver microsomes: in vitro modulation by therapeutic retinoids. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 609-612.	1.1	5
88	The Role of N-Glycosylation in Maintaining the Transporter Activity and Expression of Human Oligopeptide Transporter 1. <i>Molecular Pharmaceutics</i> , 2016, 13, 3449-3456.	2.3	5
89	Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 129, 87-98.	1.9	5
90	Impaired Transport Activity of Human Organic Anion Transporters (OATs) and Organic Anion Transporting Polypeptides (OATPs) by Wnt Inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 914-924.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery. <i>Current Medicinal Chemistry</i> , 2020, 27, 1670-1689.	1.2	5
92	The aryl-ureido fatty acid CTU activates endoplasmic reticulum stress and PERK/NOXA-mediated apoptosis in tumor cells by a dual mitochondrial-targeting mechanism. <i>Cancer Letters</i> , 2022, 526, 131-141.	3.2	5
93	Quantitative Structure-Activity Relationships in the Displacement of the Dihydrosafole Metabolite-Cytochrome P-450 Complex. <i>QSAR and Combinatorial Science</i> , 1985, 4, 18-22.	1.4	4
94	Carboxylate Analogues of Aryl-urea-Substituted Fatty Acids That Target the Mitochondria in MDA-MB-231 Breast Cancer Cells to Promote Cell Death. <i>ChemMedChem</i> , 2018, 13, 1036-1043.	1.6	4
95	Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. <i>Chemico-Biological Interactions</i> , 2021, 338, 109401.	1.7	4
96	Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib. <i>AAPS Journal</i> , 2019, 21, 107.	2.2	2
97	Carbon Chain Length Modulates MDA-MB-231 Breast Cancer Cell Killing Mechanisms by Mitochondrially Targeted Aryl-urea Fatty Acids. <i>ChemMedChem</i> , 2020, 15, 247-255.	1.6	2
98	The application of natural compounds in uveal melanoma drug discovery. <i>Journal of Pharmacy and Pharmacology</i> , 2022, 74, 660-680.	1.2	2
99	Different effects of short- and long-term dietary choline-deficiency on hepatic microsomal phospholipids and drug oxidation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 27-33.	1.4	1
100	Cytochromes P450: Roles in the Biotransformation of Chemicals in Cigarette Smoke and Impact of Smoking Cessation on Concurrent Drug Therapy. <i>Journal of Smoking Cessation</i> , 2010, 5, 107-114.	0.3	1
101	Inhibition of hepatic microsomal monooxygenase activity by cinchocaine: mechanistic studies and effects of ionization. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 38, 472-475.	1.2	1
102	Liquid Chromatography-Tandem Mass Spectrometry Assay Suitable for Quantifying Omega-3 Epoxy-Fatty Acid Analogs in Mouse Brain and Plasma. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2015, 38, 891-897.	0.5	1
103	The unfolded protein response and the biology of uveal melanoma. <i>Biochimie</i> , 2022, 197, 9-18.	1.3	1
104	The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 601-619.	2.1	1
105	PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling. <i>Biochemical Pharmacology</i> , 2021, 192, 114726.	2.0	0
106	Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. <i>Journal of Pharmaceutical Sciences</i> , 2022, , .	1.6	0